A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
暂无分享,去创建一个
Tomoaki Tanaka | A. Shimatsu | S. Midorikawa | Masahiko Sato | F. Satoh | Tomomi Kaneko | M. Ujihara | Akina Suzuki | T. Kaneko | Tamami Takeda